ArticleNucleic acids research2007
A non-covalent peptide-based carrier for in vivo delivery of DNA mimics.
Article in Nucleic acids research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 121 citations in OpenAlex.
- Mechanistic design of cell-penetrating disruptors for phospho-dependent TACC3-CHC interaction.Structure (London, England : 1993) · 2026Article
- TargetingInternational journal of molecular sciences · 2025Article
- Novel meriolin derivatives potently inhibit cell cycle progression and transcription in leukemia and lymphoma cells via inhibition of cyclin-dependent kinases (CDKs).Cell death discovery · 2024Article
- Evaluation of genotoxicity of SUNACTIVE Zn-P240 in vitro and in vivo.Toxicological research · 2022Article
- Peptide-based delivery of therapeutics in cancer treatment.Materials today. Bio · 2022Review
- Preparation of siRNA-PLGA/Fab'-PLGA mixed micellar system with target cell-specific recognition.Scientific reports · 2021Article
- Regulating Stem Cell-Related Genes Induces the Plastic Differentiation of Cancer Stem Cells to Treat Breast Cancer.Molecular therapy oncolytics · 2020Article
- Caspase-Activated Oligonucleotide Probe.Bioconjugate chemistry · 2020Article
- Activation of cell-penetrating peptide fragments by disulfide formation.Amino acids · 2020Article
- Antibacterial Peptide Nucleic Acids-Facts and Perspectives.Molecules (Basel, Switzerland) · 2020Review
- Cell-Penetrating Peptides as a Tool for the Cellular Uptake of a Genetically Modified Nitroreductase for use in Directed Enzyme Prodrug Therapy.Journal of functional biomaterials · 2019Article
- Recent Advances in Cell Penetrating Peptide-Based Anticancer Therapies.Molecules (Basel, Switzerland) · 2019Review
- Cell penetrating peptides in preclinical and clinical cancer diagnosis and therapy.Oncotarget · 2018Review
- Novel DNA Aptamers for Parkinson's Disease Treatment Inhibit α-Synuclein Aggregation and Facilitate its Degradation.Molecular therapy. Nucleic acids · 2018Article
- Therapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers.Pharmaceutics · 2018Review
- Prediction of Cell-Penetrating Potential of Modified Peptides Containing Natural and Chemically Modified Residues.Frontiers in microbiology · 2018Article
- Article
- Magnetic Nanoparticle Assisted Self-assembly of Cell Penetrating Peptides-Oligonucleotides Complexes for Gene Delivery.Scientific reports · 2017Article
- Comparison of Modular PEG Incorporation Strategies for Stabilization of Peptide-siRNA Nanocomplexes.Bioconjugate chemistry · 2016Article
- Delivery strategies and potential targets for siRNA in major cancer types.Advanced drug delivery reviews · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The dramatic acceleration in identification of new nucleic-acid-based therapeutic molecules has provided new perspectives in pharmaceutical research. However, their development is limited by their poor cellular uptake and inefficient trafficking. Here we describe a short amphipathic peptide, Pep-3, that combines a tryptophan/phenylalanine domain with a lysine/arginine-rich hydrophilic motif. Pep-3 forms stable nano-size complexes with peptide-nucleic acid analogues and promotes their efficient delivery into a wide variety of cell lines, including primary and suspension lines, without any associated cytotoxicity. We demonstrate that Pep-3-mediated delivery of antisense-cyclin B1-charged-PNA blocks tumour growth in vivo upon intratumoral and intravenous injection. Moreover, we show that PEGylation of Pep-3 significantly improves complex stability in vivo and consequently the efficiency of antisense cyclin B1 administered intravenously. Given the biological characteristics of these vectors, we believe that peptide-based delivery technologies hold a true promise for therapeutic applications of DNA mimics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.